VCI Global: MACD Death Cross, Bearish Marubozu on 15min chart

According to VCI Global's 15-minute chart, a MACD Death Cross and a Bearish Marubozu pattern have emerged as of 10/03/2025 14:45. This suggests that the stock price has the potential to continue declining, with sellers dominating the market and bearish momentum likely to persist.

Corvus Pharmaceuticals (CRVS), a clinical-stage biopharmaceutical company, has seen a mixed reaction in the market as of October 3, 2025. According to VCI Global's 15-minute chart, a MACD Death Cross and a Bearish Marubozu pattern have emerged, indicating potential further decline in the stock price. This suggests that sellers are dominating the market, and bearish momentum is likely to persist Corvus Pharmaceu Stock Price, News & Analysis^[1].

Despite the bearish indicators, Corvus Pharmaceuticals has reported significant clinical progress. The company's lead drug candidate, soquelitinib, showed promising results in Phase 1 trials for atopic dermatitis, with cohort 3 achieving a 64.8% mean EASI reduction compared to 34.4% for placebo . Additionally, the company has announced a Phase 1b/2 clinical trial of soquelitinib in China for the treatment of atopic dermatitis, with patient enrollment expected to begin in Q3 2025 .

Financially, Corvus Pharmaceuticals has strengthened its position with warrant exercises providing $35.7 million in proceeds during Q2 2025, ending the quarter with $74.4 million in cash. The company expects its cash runway to extend into Q4 2026 . However, the company reported a net loss of $8.0 million in Q2 2025, with R&D expenses increasing to $7.9 million .

The company's stock price has been volatile, with the current stock price of Corvus Pharmaceu (CRVS) at $7.26 as of October 1, 2025 . The market cap of Corvus Pharmaceu (CRVS) is approximately 549.2M .

Corvus Pharmaceuticals is scheduled to provide its second quarter 2025 financial results and business update on August 7, 2025 . The company's leadership team will also participate in the 2025 Jefferies Global Healthcare Conference in New York on June 5, 2025 .

While the clinical data is promising, the market's bearish sentiment and financial challenges may pose significant hurdles for Corvus Pharmaceuticals in the near future.